All lobbying filings

LEAVITT PARTNERS, LLC

LEAVITT PARTNERS, LLC filed a Q3 report for ALLIANCE FOR MRNA MEDICINES on October 20, 2026, reporting $20,000 in lobbying income.

Lobbying for ALLIANCE FOR MRNA MEDICINES · Multi-organization alliance representing the MRNA sector.

All filings by LEAVITT PARTNERS, LLC · Everything ALLIANCE FOR MRNA MEDICINES has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$20,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 2

ROBERT CLAYTON ALSPACH

Previously held: Chief Health Counsel for Chairman - House E&C Committee (E&C);Counsel - E&C, Clerk - E&C, and Paid Intern - E&C
SARA SINGLETON

Previously held: Deputy Assistant Secretary-HHS; Policy Advisor- Senate; Legislative Assistant- Senate; Policy Fellow- Senate

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

The Alliance for mRNA Medicines (AMM) is dedicated to advancing and advocating for an RNA platform approach to medicine, including protein replacements, gene editing and cell engineering strategies, immunotherapies and vaccines to treat cancer, rare disease, autoimmunity and other chronic and infectious illnesses for the benefit of patients, public health, and society.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.